Vera Therapeutics (VERA) Other financing activities (2020 - 2026)

Vera Therapeutics' Other financing activities history runs 7 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• Quarterly Other financing activities rose 157.14% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 million (up 16.86% YoY) and the FY2025 annual result came in at $7.0 million, down 47.95% from the prior year.
• Other financing activities was $3.9 million for Q1 2026 at Vera Therapeutics, down from $4.2 million in the prior quarter.
• Across five years, Other financing activities topped out at $6.9 million in Q1 2024 and bottomed at $47000.0 in Q2 2022.
• A 5-year average of $1.6 million and a median of $797000.0 in 2025 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities tumbled 99.91% — and 2024, when it jumped 2779.58%.
• Vera Therapeutics' Other financing activities stood at $827000.0 in 2022, then plunged by 89.48% to $87000.0 in 2023, then soared by 2556.32% to $2.3 million in 2024, then surged by 81.18% to $4.2 million in 2025, then slipped by 5.85% to $3.9 million in 2026.
• Business Quant data shows VERA's Other financing activities at $3.9 million in Q1 2026, $4.2 million in Q4 2025, and $797000.0 in Q3 2025.